A critical review of treatment modalities for blastic plasmacytoid dendritic cell neoplasm. (November 2016)

• Record Type: Journal Article
• Authors: Falcone, Umberto; Sibai, Hassan; Deotare, Uday
• Is Part Of: Critical reviews in oncology/hematology. Volume 107(2016)
• Page Start: 156
• Page End: 162
• Publication Date: 2016-11
• Subjects: Blastic plasmacytoid dendritic cell neoplasm -- HyperCVAD -- Allogeneic hematopoeitic cell transplant -- Autologous hematopoeitic cell transplant; Oncology -- Periodicals; Hematology -- Periodicals; 616.994
• DOI: 10.1016/j.critrevonc.2016.09.003
• Languages: English
• ISSNs: 1040-8428

Abstract

Abstract: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a clinically aggressive tumor derived from the precursors of plasmacytoid dendritic cells. It is a rare disease presenting across all ages with either skin or both skin and bone marrow involvement often conferring a poor prognosis. Though localized radiation has been used before, acute leukemia based regimens, remains the treatment of choice for induction of remission. Hematopoietic stem cell transplant, either autologous or allogeneic, is further required for attaining sustained remissions. Recently, a number of targeted therapies and newer drugs have been used as the molecular and genetic understanding of the disease have improved.